The government has banned the widely prescribed anti-diabetes drug pioglitazone in the wake of claimed health risks
associated with the drug.
The decision to ban pioglitazone and its combinations will hit the
Rs 700-crore market for such drugs and adversely impact a clutch of
companies including Abbott, Sun Pharma, USV, Lupin, Ranbaxy and
Pioglitazone combination is a bigger market than plain
pioglitazone itself which is has posted a strong double-digit growth,
with over 30 companies marketing the drug. The top-selling brands of
posiglitazone include Pioz MF G and Pioz (USV), Gemer P (Sun Pharma),
Tribet (Abbott), Tripride (Micro Labs) and Gluconorm PG (Lupin).